Deal Details

• Nuvama garnered participation from a diverse investor set across FII and DII Investors
• Pushed the story aggressively through our distribution channel to garner strong interest in HNI & Retail category resulting in 33 lakh+ applications^#
• Nuvama worked closely with the Company through the entire IPO process including post issue activities to ensure smooth and successful closure
• Nuvama leveraged its strong understanding of the industry to uniquely position Senores Pharma as a global research-driven pharmaceutical company

Contribution

• Highest subscribed Pharma IPO in India over the last decade
• IPO received significant oversubscription across investor categories garnering more than INR 31,000 crs^#
  • QIB – ~99x*, HNI – ~98x*, Retail – ~95x*
• Company saw stellar IPO Listing with equity shares opening at 53%^ premium showcasing investor confidence in Company’s business and management team
  

^NSE Prices are considered on listing day; *After technical Rejections; #Before technical Rejections